Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Integra Lifesciences Holdings (IART) Accumulated Expenses (2016 - 2025)

Integra Lifesciences Holdings' Accumulated Expenses history spans 17 years, with the latest figure at $130.5 million for Q4 2025.

  • For Q4 2025, Accumulated Expenses rose 7.04% year-over-year to $130.5 million; the TTM value through Dec 2025 reached $130.5 million, up 7.04%, while the annual FY2025 figure was $130.5 million, 7.04% up from the prior year.
  • Accumulated Expenses for Q4 2025 was $130.5 million at Integra Lifesciences Holdings, up from $75.0 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $131.9 million in Q3 2024 and bottomed at $52.4 million in Q1 2025.
  • The 5-year median for Accumulated Expenses is $85.2 million (2022), against an average of $90.1 million.
  • The largest annual shift saw Accumulated Expenses soared 62.43% in 2023 before it tumbled 53.19% in 2025.
  • A 5-year view of Accumulated Expenses shows it stood at $92.7 million in 2021, then dropped by 13.62% to $80.0 million in 2022, then grew by 26.0% to $100.8 million in 2023, then increased by 20.89% to $121.9 million in 2024, then rose by 7.04% to $130.5 million in 2025.
  • Per Business Quant, the three most recent readings for IART's Accumulated Expenses are $130.5 million (Q4 2025), $75.0 million (Q3 2025), and $131.4 million (Q2 2025).